These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 9771090)

  • 21. Emedastine and allergic conjunctivitis: new preparation. Poor assessment.
    Prescrire Int; 2001 Apr; 10(52):39-40. PubMed ID: 11718155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.
    Borazan M; Karalezli A; Akova YA; Akman A; Kiyici H; Erbek SS
    Acta Ophthalmol; 2009 Aug; 87(5):549-54. PubMed ID: 18631332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epinastine 0.05% ophthalmic solution in contact lens-wearing subjects with a history of allergic conjunctivitis.
    Nichols KK; Morris S; Gaddie IB; Evans D
    Eye Contact Lens; 2009 Jan; 35(1):26-31. PubMed ID: 19125045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lodoxamide for vernal keratoconjunctivitis.
    Med Lett Drugs Ther; 1994 Mar; 36(918):26. PubMed ID: 8121328
    [No Abstract]   [Full Text] [Related]  

  • 25. Randomised double-masked trial of lodoxamide and sodium cromoglycate in allergic eye disease. A multicentre study.
    Fahy GT; Easty DL; Collum LM; Benedict-Smith A; Hillery M; Parsons DG
    Eur J Ophthalmol; 1992; 2(3):144-9. PubMed ID: 1450659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis.
    Abelson MB; Gomes PJ; Vogelson CT; Pasquine TA; Turner FD; Wells DT; Robertson SM
    Curr Med Res Opin; 2005 May; 21(5):683-91. PubMed ID: 15969867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vernal keratoconjunctivitis presenting unilaterally.
    Awwad ST; Najjar DM; Arlette A; Haddad RS
    J Pediatr Ophthalmol Strabismus; 2006; 43(3):179-80. PubMed ID: 16761642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Evaluation of the efficacy and safety of lodoxamide in patients with allergic eye diseases].
    Dekaris I; Gabrić N; Lazić R; Bosnar D; Cima I; Stipić A
    Acta Med Croatica; 2002; 56(3):93-8. PubMed ID: 12630339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Allergodil eye drops in the treatment of allergic conjunctivitis].
    Haicl P; Cerná H
    Cesk Slov Oftalmol; 2002 Jul; 58(4):254-8. PubMed ID: 12181881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Olopatadine for allergic conjunctivitis.
    Med Lett Drugs Ther; 1997 Nov; 39(1014):108-9. PubMed ID: 9398823
    [No Abstract]   [Full Text] [Related]  

  • 31. [Cyclosporin A 2% eyedrops in therapy of atopic and vernal keratoconjunctivitis].
    Tomida I; Schlote T; Bräuning J; Heide PE; Zierhut M
    Ophthalmologe; 2002 Oct; 99(10):761-7. PubMed ID: 12376851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elestat (epinastine HCl ophthalmic solution 0.05%) as a therapeutic for allergic conjunctivitis.
    Trattler WB; Luchs J; Majmudar P
    Int Ophthalmol Clin; 2006; 46(4):87-99. PubMed ID: 17060795
    [No Abstract]   [Full Text] [Related]  

  • 33. [Allergic conditions of the eye].
    Thurau S
    MMW Fortschr Med; 2004 Feb; 146(7):41-4. PubMed ID: 15347048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Therapy of allergic conjunctivitis].
    Hidasi V
    Orv Hetil; 2000 Aug; 141(34):1859-65. PubMed ID: 11006710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.
    Abelson MB; Greiner JV
    Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Value of the conjunctival provocation test in evaluating the activity of 2 concentrations of anti-allergy eyedrops, mequitazine].
    Dupin O; Compeyre S; Trinquand C; Persi L; Arnaud B
    J Fr Ophtalmol; 1998 Jan; 21(1):12-8. PubMed ID: 9834894
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical evaluation of Spersallerg preparation for non-infectious conjunctivitis and infectious conjunctivitis with a hyperergic component].
    Nizankowska MH; Lukasik-Czerek A
    Klin Oczna; 1996 Jan; 98(1):41-3. PubMed ID: 9019574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of azelastine eye drops with levocabastine eye drops in the treatment of seasonal allergic conjunctivitis.
    Giede C; Metzenauer P; Petzold U; Ellers-Lenz B
    Curr Med Res Opin; 2000; 16(3):153-63. PubMed ID: 11191004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of a combined therapy with a histamine H1 antagonist and a chemical mediator release inhibitor on allergic conjunctivitis.
    Fujishima H; Fukagawa K; Tanaka M; Uchio E; Takamura E; Nakagawa Y; Miyazaki D; Fukushima A; Okamoto S; Yokoi N
    Ophthalmologica; 2008; 222(4):232-9. PubMed ID: 18463425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Topical bromfenac sodium for long-term management of vernal keratoconjunctivitis.
    Uchio E; Itoh Y; Kadonosono K
    Ophthalmologica; 2007; 221(3):153-8. PubMed ID: 17440276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.